Clinical trial
Bevacizumab With or Without Docetaxel in Treating Patients With Previously…
NCT00066677 · Fox Chase Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00066677 |
|---|---|
| Title | Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer |
| Official title | Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | rhuMAB-VEGF, docetaxel |
| Enrollment | 32 |
| Start date | Oct 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Aug 7, 2003 |
| Last update posted | Mar 5, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: